4.11 USD
▲+0.16+3.27%
盘后 3.91 -1.76%
2026-08-03
市值
$429.01M
市盈率
—
EPS
-2.09
股息率
—
52 周区间
2.72 – 6.42
成交量
1.68M
Beta
0.84
目标价
14.40
52W 低 2.7252W 高 6.42
价格走势
公司简介
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich’s ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.